6-(2-methoxybiphenyl)-2,2,4-trimethyl-1,2-dihydroquinoline | 666726-32-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-(2-methoxybiphenyl)-2,2,4-trimethyl-1,2-dihydroquinoline
• 英文别名: 6-(2-Methoxyphenyl)-2,2,4-trimethyl-1,2-dihydroquinoline；6-(2-methoxyphenyl)-2,2,4-trimethyl-1H-quinoline
• CAS: 666726-32-5
• 化学式: C₁₉H₂₁NO
• 分子量: 279.382
• InChiKey: QRLZVPMAUWNKEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-(2-methoxybiphenyl)-2,2,4-trimethyl-1,2-dihydroquinoline 在 正丁基锂 、 selenium(IV) oxide 、 sodium hexamethyldisilazane 、 三氟乙酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 11.67h， 生成 4-(1-allyloxy-2-methylpropyl)-6-(2-methoxyphenyl)-2,2-dimethyl-1,2-dihydroquinoline
  参考文献：
  名称：

  Discovery and SAR study of novel dihydroquinoline-containing glucocorticoid receptor agonists

  摘要：

  We have recently reported the discovery of a novel class of glucocorticoid receptor (GR) antagonists, exemplified by 3, containin-v a 1.2-dihydroquinoline molecular scaffold. Further SAR studies of these antagonists uncovered chemical modifications conveying agonist functional activity to this series. These agonists exhibit good GR binding affinity and are selective against other nuclear hormone receptors. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.07.021
• 作为产物：
  描述：

  1-甲氧基-2-(4-硝基苯基)苯 在 palladium on activated charcoal 碘 、 甲酸铵 、 magnesium sulfate 作用下， 以 甲醇 为溶剂， 反应 3.42h， 生成 6-(2-methoxybiphenyl)-2,2,4-trimethyl-1,2-dihydroquinoline
  参考文献：
  名称：

  Discovery and SAR study of novel dihydroquinoline containing glucocorticoid receptor ligands

  摘要：

  We report the discovery of a novel class of glucocorticoid receptor (GR) ligands based on 1,2-dihydroquinoline molecular scaffold. The compounds exhibit good GR binding affinity and selectivity profile against other nuclear hormone receptors. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.043

文献信息

• Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US20040116455A1

  公开（公告）日：2004-06-17

  Compounds of Formula (I) 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, Y, and n are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

  化合物公式（I）的化合物，其中R1，R2，R3，R4，R5，R6，X，Y和n如此定义，或其互变异构体，前药，溶剂合物或盐；包含这些化合物的制药组合物，以及使用这些化合物调节糖皮质激素受体功能的方法和用于治疗患有炎症，过敏或增生过程的疾病状态或情况的方法。
• [EN] SUBSTITUTED HIHYDROQUINOLINES AS GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF<br/>[FR] COMPOSES MIMETIQUES DE GLUCOCORTICOIDE, LEURS PROCEDES DE FABRICATION, COMPOSITIONS PHARMACEUTIQUES, ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2004018429A3

  公开（公告）日：2004-06-10
• SUBSTITUTED HIHYDROQUINOLINES AS GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
  申请人：BOEHRINGER INGELHEIM PHARMACEUTICALS INC.

  公开号：EP1532113A2

  公开（公告）日：2005-05-25
• US6858627B2
  申请人：——

  公开号：US6858627B2

  公开（公告）日：2005-02-22
• Discovery and SAR study of novel dihydroquinoline containing glucocorticoid receptor ligands
  作者：Hidenori Takahashi、Younes Bekkali、Alison J. Capolino、Thomas Gilmore、Susan E. Goldrick、Richard M. Nelson、Donna Terenzio、Ji Wang、Ljiljana Zuvela-Jelaska、John Proudfoot、Gerald Nabozny、David Thomson

  DOI：10.1016/j.bmcl.2005.12.043

  日期：2006.3

  We report the discovery of a novel class of glucocorticoid receptor (GR) ligands based on 1,2-dihydroquinoline molecular scaffold. The compounds exhibit good GR binding affinity and selectivity profile against other nuclear hormone receptors. (C) 2005 Elsevier Ltd. All rights reserved.